A high number of stromal tumor-infiltrating lymphocytes is a favorable independent prognostic factor in M0 (stages I-III) esophageal squamous cell carcinoma

被引:9
作者
Li, Jing [1 ]
Tang, Yang [1 ]
Huang, Liu [1 ]
Yu, Qianqian [1 ]
Hu, Guangyuan [1 ]
Zou, Yanmei [1 ]
Yuan, Xianglin [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Oncol, Tongji Hosp, Tongji Med Coll, Jiefang Rd 1095, Wuhan 430030, Hubei Province, Peoples R China
关键词
disease-free survival; esophageal squamous cell carcinoma; overall survival; prognostic factor; tumor-infiltrating lymphocyte; BREAST-CANCER; IMMUNE-RESPONSE; T-CELLS; CHEMOTHERAPY; SURVIVAL;
D O I
10.1111/dote.12518
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Esophageal cancer is a highly invasive tumor with a poor prognosis. Lymphocytes play an important role in systemic immune responses, but their role in cancers varies depending on the specific tumor microenvironment. The aim of this study was to provide evidence for tumor-infiltrating lymphocytes (TILs) as a prognostic biomarker in esophageal squamous cell carcinoma. TIL analysis was retrospectively performed on full-face hematoxylin and eosin-stained sections from 127 patients. A majority (92.6%) of tumors had at least 10% stromal TILs (sTILs) (range, 10%-90%), and 84.3% of cancers had at least 10% intraepithelial TILs (iTILs) (range, 10%-40%). Multivariate analysis showed progressively better overall survival (P < 0.001, hazard ratio = 0.968, 95% confidence interval 0.955-0.981) and disease-free survival (P = 0.005, hazard ratio = 0.982, 95% confidence interval 0.970-0.995) in patients with higher sTILs. Marginal increases in overall survival and disease-free survival were found in the higher iTILs cohort versus the lower iTILs cohort, but the difference was not significant. In conclusion, in addition to tumor stage increasing stromal lymphocytic infiltration is an independent prognostic factor for esophageal squamous cell carcinoma treated by radical resection.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 22 条
[1]   LYMPHOCYTE INFILTRATES AS A PROGNOSTIC VARIABLE IN FEMALE BREAST-CANCER [J].
AALTOMAA, S ;
LIPPONEN, P ;
ESKELINEN, M ;
KOSMA, VM ;
MARIN, S ;
ALHAVA, E ;
SYRJANEN, K .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (4-5) :859-864
[2]   Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].
Adams, Sylvia ;
Gray, Robert J. ;
Demaria, Sandra ;
Goldstein, Lori ;
Perez, Edith A. ;
Shulman, Lawrence N. ;
Martino, Silvana ;
Wang, Molin ;
Jones, Vicky E. ;
Saphner, Thomas J. ;
Wolff, Antonio C. ;
Wood, William C. ;
Davidson, Nancy E. ;
Sledge, George W. ;
Sparano, Joseph A. ;
Badve, Sunil S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+
[3]  
Adham M, 2000, CANCER, V89, P946
[4]   Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years [J].
Ando, N ;
Ozawa, S ;
Kitagawa, Y ;
Shinozawa, Y ;
Kitajima, M .
ANNALS OF SURGERY, 2000, 232 (02) :225-232
[5]  
[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
[6]   The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Criollo, Alfredo ;
Ortiz, Carla ;
Lidereau, Rosette ;
Mariette, Christophe ;
Chaput, Nathalie ;
Mira, Jean-Paul ;
Delaloge, Suzette ;
Andre, Fabrice ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
IMMUNOLOGICAL REVIEWS, 2007, 220 :47-59
[7]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[8]   Correlation of p53, MDM2 and p14ARF protein expression in human esophageal squamous cell carcinoma [J].
Cheng, Tzu-Hao ;
Hsu, Po-Kuei ;
Li, Anna Fen-Yau ;
Hung, I-Chun ;
Huang, Min-Hsiung ;
Hsu, Han-Shui .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (11) :1577-1582
[9]   Inflammation and breast cancer - Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression [J].
DeNardo, David G. ;
Coussens, Lisa M. .
BREAST CANCER RESEARCH, 2007, 9 (04)
[10]   Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers [J].
Denkert, Carsten ;
von Minckwitz, Gunter ;
Brase, Jan C. ;
Sinn, Bruno V. ;
Gade, Stephan ;
Kronenwett, Ralf ;
Pfitzner, Berit M. ;
Salat, Christoph ;
Loi, Sherene ;
Schmitt, Wolfgang D. ;
Schem, Christian ;
Fisch, Karin ;
Darb-Esfahani, Silvia ;
Mehta, Keyur ;
Sotiriou, Christos ;
Wienert, Stephan ;
Klare, Peter ;
Andre, Fabrice ;
Klauschen, Frederick ;
Blohmer, Jens-Uwe ;
Krappmann, Kristin ;
Schmidt, Marcus ;
Tesch, Hans ;
Kuemmel, Sherko ;
Sinn, Peter ;
Jackisch, Christian ;
Dietel, Manfred ;
Reimer, Toralf ;
Untch, Michael ;
Loibl, Sibylle .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :983-991